Can the Life Sciences strategy become a reality?
06 October 2017
The House of Lords Science and Technology Committee holds the first evidence sessions on its new inquiry into Life Sciences and the Industrial Strategy, and hears evidence from across the scientific community.
Purpose of session
The evidence session is an opportunity for the Committee to hear the witness's reactions to Sir John Bell’s Life Sciences Industrial Strategy, identify areas which they feel could be improved and discuss how it can be implemented.
Tuesday 10 October in Committee Room 4A, Palace of Westminster
- Dr Annette Bramley, Head of Healthcare Technologies, Engineering and Physical Sciences Research Council (EPSRC)
- Sir John Savill, Chief Executive, Medical Research Council (MRC)
- Louise Wren, Policy Adviser, Wellcome Trust
- Sir Harpal Kumar, Chief Executive Officer, Cancer Research UK
- Professor James Stirling CBE FRS, Provost, Imperial College London
- Professor David Price FGS, Vice-Provost, University College London
- Professor John Atherton, Pro Vice Chancellor and Dean of the School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham
- Professor Chris Lowe OBE, University of Cambridge
- Professor Philip Nelson, Chair, Research Councils UK (RCUK)
Questions likely to be covered in the sessions include:
- Who should be responsible for delivering the Life Sciences Strategy and to whom should they be accountable?
- Should the Government appoint a Life Sciences Minister?
- Are there any features in the strategy – or any gaps?
- How can collaboration between researchers and the NHS be improved, particularly in light of increased fiscal pressures in the NHS?
More news on: Parliament, government and politics, Parliament, Business, industry and consumers, Science and technology, Research and innovation, Science, Industry, House of Lords news, Lords news, Committee news
Share this page